Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 264

1.

Emerging Applications of Optical Coherence Tomography Angiography (OCTA) in neurological research.

Wang L, Murphy O, Caldito NG, Calabresi PA, Saidha S.

Eye Vis (Lond). 2018 May 12;5:11. doi: 10.1186/s40662-018-0104-3. eCollection 2018. Review.

2.

Anti-calponin-3 autoantibodies: a new specificity in patients with Sjögren's syndrome.

Birnbaum J, Hoke A, Lalji A, Calabresi P, Bhargava P, Casciola-Rosen L.

Arthritis Rheumatol. 2018 May 11. doi: 10.1002/art.40550. [Epub ahead of print]

PMID:
29749720
3.

Dice Overlap Measures for Objects of Unknown Number: Application to Lesion Segmentation.

Oguz I, Carass A, Pham DL, Roy S, Subbana N, Calabresi PA, Yushkevich PA, Shinohara RT, Prince JL.

Brainlesion (2017). 2018;10670:3-14. doi: 10.1007/978-3-319-75238-9_1. Epub 2018 Feb 17.

PMID:
29714358
4.

Joint Intensity Fusion Image Synthesis Applied to Multiple Sclerosis Lesion Segmentation.

Fleishman GM, Valcarcel A, Pham DL, Roy S, Calabresi PA, Yushkevich P, Shinohara RT, Oguz I.

Brainlesion (2017). 2018;10670:43-54. Epub 2018 Feb 17.

PMID:
29714357
5.

Multiple Sclerosis Lesion Segmentation Using Joint Label Fusion.

Dong M, Oguz I, Subbana N, Calabresi P, Shinohara RT, Yushkevich P.

Patch Based Tech Med Imaging (2017). 2017 Sep;10530:138-145. doi: 10.1007/978-3-319-67434-6_16. Epub 2017 Aug 31.

6.

Visual Pathway Measures are Associated with Neuropsychological Function in Multiple Sclerosis.

Nguyen J, Rothman A, Fitzgerald K, Whetstone A, Syc-Mazurek S, Aquino J, Balcer LJ, Frohman EM, Frohman TC, Crainiceanu C, Beier M, Newsome SD, Calabresi PA, Saidha S.

Curr Eye Res. 2018 Jul;43(7):941-948. doi: 10.1080/02713683.2018.1459730. Epub 2018 May 1.

PMID:
29634379
7.

Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity.

Kornberg MD, Bhargava P, Kim PM, Putluri V, Snowman AM, Putluri N, Calabresi PA, Snyder SH.

Science. 2018 Apr 27;360(6387):449-453. doi: 10.1126/science.aan4665. Epub 2018 Mar 29.

PMID:
29599194
8.

MIMoSA: An Automated Method for Intermodal Segmentation Analysis of Multiple Sclerosis Brain Lesions.

Valcarcel AM, Linn KA, Vandekar SN, Satterthwaite TD, Muschelli J, Calabresi PA, Pham DL, Martin ML, Shinohara RT.

J Neuroimaging. 2018 Mar 8. doi: 10.1111/jon.12506. [Epub ahead of print]

PMID:
29516669
9.

Central vein sign in multiple sclerosis: Ready for front and center?

Miller AE, Calabresi PA.

Neurology. 2018 Apr 3;90(14):631-632. doi: 10.1212/WNL.0000000000005241. Epub 2018 Mar 7. No abstract available.

PMID:
29514945
10.

Bryostatin-1 alleviates experimental multiple sclerosis.

Kornberg MD, Smith MD, Shirazi HA, Calabresi PA, Snyder SH, Kim PM.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2186-2191. doi: 10.1073/pnas.1719902115. Epub 2018 Feb 12.

PMID:
29440425
11.

Optimal Intereye Difference Thresholds in Retinal Nerve Fiber Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis.

Nolan RC, Galetta SL, Frohman TC, Frohman EM, Calabresi PA, Castrillo-Viguera C, Cadavid D, Balcer LJ.

J Neuroophthalmol. 2018 Jan 29. doi: 10.1097/WNO.0000000000000629. [Epub ahead of print]

PMID:
29384802
12.

Defining response profiles after alemtuzumab: Rare paradoxical disease exacerbation.

Wiendl H, Calabresi PA, Meuth SG.

Neurology. 2018 Feb 13;90(7):309-311. doi: 10.1212/WNL.0000000000004969. Epub 2018 Jan 19. No abstract available.

PMID:
29352097
13.

Multiple Sclerosis.

Reich DS, Lucchinetti CF, Calabresi PA.

N Engl J Med. 2018 Jan 11;378(2):169-180. doi: 10.1056/NEJMra1401483. Review. No abstract available.

PMID:
29320652
14.

Advances in multiple sclerosis: from reduced relapses to remedies.

Calabresi PA.

Lancet Neurol. 2018 Jan;17(1):10-12. doi: 10.1016/S1474-4422(17)30417-9. Epub 2017 Dec 16. No abstract available.

PMID:
29262991
15.

Analysis of Agreement of Retinal-Layer Thickness Measures Derived from the Segmentation of Horizontal and Vertical Spectralis OCT Macular Scans.

Gonzalez Caldito N, Antony B, He Y, Lang A, Nguyen J, Rothman A, Ogbuokiri E, Avornu A, Balcer L, Frohman E, Frohman TC, Bhargava P, Prince J, Calabresi PA, Saidha S.

Curr Eye Res. 2018 Mar;43(3):415-423. doi: 10.1080/02713683.2017.1406526. Epub 2017 Dec 14.

PMID:
29240464
16.

Distinguishing among multiple sclerosis fallers, near-fallers and non-fallers.

Fritz NE, Eloyan A, Baynes M, Newsome SD, Calabresi PA, Zackowski KM.

Mult Scler Relat Disord. 2018 Jan;19:99-104. doi: 10.1016/j.msard.2017.11.019. Epub 2017 Nov 22.

PMID:
29182996
17.

Characteristics of morphologic macular abnormalities in neuroimmunology practice.

Al-Louzi O, Sotirchos ES, Vidal-Jordana A, Beh SC, Button J, Ying HS, Balcer LJ, Frohman EM, Saidha S, Calabresi PA, Newsome SD.

Mult Scler. 2017 Nov 1:1352458517741206. doi: 10.1177/1352458517741206. [Epub ahead of print]

PMID:
29125422
18.

Dimethyl fumarate treatment alters NK cell function in multiple sclerosis.

Smith MD, Calabresi PA, Bhargava P.

Eur J Immunol. 2018 Feb;48(2):380-383. doi: 10.1002/eji.201747277. Epub 2017 Dec 15.

PMID:
29108094
19.

The NAIMS cooperative pilot project: Design, implementation and future directions.

Oh J, Bakshi R, Calabresi PA, Crainiceanu C, Henry RG, Nair G, Papinutto N, Constable RT, Reich DS, Pelletier D, Rooney W, Schwartz D, Tagge I, Shinohara RT, Simon JH, Sicotte NL; NAIMS Cooperative Steering Committee.

Mult Scler. 2017 Oct 1:1352458517739990. doi: 10.1177/1352458517739990. [Epub ahead of print]

PMID:
29106329
20.

Cell-based therapeutic strategies for multiple sclerosis.

Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis.

Brain. 2017 Nov 1;140(11):2776-2796. doi: 10.1093/brain/awx154. Review.

Supplemental Content

Loading ...
Support Center